The pharmacokinetics of oxybutynin in man.
We have studied the pharmacokinetics of oxybutynin (Ditropan) after single oral (5 mg) and intravenous administration (1 and 5 mg), and after repeated oral administration in healthy volunteers. Oxybutynin was rapidly absorbed, maximum plasma concentrations (8 ng.ml-1) being reached in less than 1 h. The absolute systemic availability averaged 6% and the tablet and solution forms displayed similar relative systemic availability. Plasma concentrations of oxybutynin fell biexponentially, the elimination half-life being about 2 h. There was a large interindividual variation in oxybutynin plasma concentrations. Almost no intact drug could be recovered in the urine. During repeated oral administration steady-state was reached after eight days of treatment. The low absolute systemic availability of oxybutynin, the large interindividual variability in its plasma concentrations, and the apparent absence of intact oxybutynin in the urine suggest that its major pathway of elimination is hepatic metabolism.
Douchamps
J
J
Unité de Pharmacologie Clinique, Hôpital Vésale, Montigny-le-Tilleul, Belgium.
Derenne
F
F
Stockis
A
A
Gangji
D
D
Juvent
M
M
Herchuelz
A
A
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D003647:Debrisoquin / Q000378:metabolism; D004361:Drug Tolerance; D005260:Female; D006207:Half-Life; D006801:Humans; D006900:Hydroxylation; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D010276:Parasympatholytics / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D012996:Solutions; D013607:Tablets
D008333:Mandelic Acids; D010276:Parasympatholytics; D012996:Solutions; D013607:Tablets; C005419:oxybutynin; D003647:Debrisoquin